Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Dexcom, Inc. securities between July 26, 2024 and September 17, 2025.
“We know from data that primary care, which sees over 90% of patients with type 2 diabetes, that there’s not much uptake or ...
Many people are wearing glucose monitors despite them not having diabetes as an approach to weight loss and to improve ...
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) DexCom had made material design changes to its G6 and G7 ...
Continuous glucose monitoring can identify unrecognized hyperglycemia and hypoglycemia in dialysis patients, challenging reliance on A1c for diabetes management.
The company showcased its advancements in type 2 diabetes continuous glucose monitoring (CGM) coverage and introduced innovative products like the DexCom Smart Basal. Despite these achievements, ...
In a significant step towards modernizing diabetes management in Sri Lanka, Tranz Pharma Holdings has officially introduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback